155 related articles for article (PubMed ID: 25367314)
21. Impact of multi-electrode renal sympathetic denervation on short-term blood pressure variability in patients with drug-resistant hypertension. Insights from the EnligHTN I study.
Tsioufis C; Papademetriou V; Tsiachris D; Kasiakogias A; Kordalis A; Thomopoulos C; Dimitriadis K; Tousoulis D; Stefanadis C; Parati G; Worthley S
Int J Cardiol; 2015 Feb; 180():237-42. PubMed ID: 25463375
[TBL] [Abstract][Full Text] [Related]
22. Economic evaluation of primary prevention of cardiovascular diseases in mild hypertension: a scenario analysis for the Netherlands.
Stevanović J; O'Prinsen AC; Verheggen BG; Schuiling-Veninga N; Postma MJ; Pechlivanoglou P
Clin Ther; 2014 Mar; 36(3):368-84.e5. PubMed ID: 24534654
[TBL] [Abstract][Full Text] [Related]
23. ESH position paper: renal denervation - an interventional therapy of resistant hypertension.
Schmieder RE; Redon J; Grassi G; Kjeldsen SE; Mancia G; Narkiewicz K; Parati G; Ruilope L; van de Borne P; Tsioufis C
J Hypertens; 2012 May; 30(5):837-41. PubMed ID: 22469838
[TBL] [Abstract][Full Text] [Related]
24. Renal denervation therapy for resistant hypertension: a clinical update.
Ram CV; Kumar AS
J Hum Hypertens; 2014 Dec; 28(12):699-704. PubMed ID: 24599151
[TBL] [Abstract][Full Text] [Related]
25. The cholinergic anti-inflammatory pathway in resistant hypertension treated with renal denervation.
Hilderman M; Qureshi AR; Abtahi F; Witt N; Jägren C; Olbers J; Delle M; Lindecrantz K; Bruchfeld A
Mol Med; 2019 Aug; 25(1):39. PubMed ID: 31416428
[TBL] [Abstract][Full Text] [Related]
26. Cost-utility analysis of bevacizumab versus ranibizumab in neovascular age-related macular degeneration using a Markov model.
Patel JJ; Mendes MA; Bounthavong M; Christopher ML; Boggie D; Morreale AP
J Eval Clin Pract; 2012 Apr; 18(2):247-55. PubMed ID: 20846318
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of renin-guided treatment of hypertension.
Smith SM; Campbell JD
Am J Hypertens; 2013 Nov; 26(11):1303-10. PubMed ID: 24048147
[TBL] [Abstract][Full Text] [Related]
28. Renal denervation for the treatment of hypertension: the Dutch consensus.
Verloop WL; Agema WR; Allaart CP; Blankestijn PJ; Khan M; Meuwissen M; Muijs van de Moer WM; Rensing BJ; Spiering W; Voskuil M; Doevendans PA;
Neth J Med; 2014 Nov; 72(9):449-54. PubMed ID: 25431389
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of statins for primary prevention in patients newly diagnosed with type 2 diabetes in the Netherlands.
de Vries FM; Denig P; Visser ST; Hak E; Postma MJ
Value Health; 2014 Mar; 17(2):223-30. PubMed ID: 24636380
[TBL] [Abstract][Full Text] [Related]
30. The effect of percutaneous renal denervation on muscle sympathetic nerve activity in hypertensive patients.
Vink EE; Verloop WL; Siddiqi L; van Schelven LJ; Liam Oey P; Blankestijn PJ
Int J Cardiol; 2014 Sep; 176(1):8-12. PubMed ID: 25027168
[TBL] [Abstract][Full Text] [Related]
31. Safety and long-term effects of renal denervation: Rationale and design of the Dutch registry.
Sanders MF; Blankestijn PJ; Voskuil M; Spiering W; Vonken EJ; Rotmans JI; van der Hoeven BL; Daemen J; van den Meiracker AH; Kroon AA; de Haan MW; Das M; Bax M; van der Meer IM; van Overhagen H; van den Born BJ; van Brussel PM; van der Valk PH; Smak Gregoor PJ; Meuwissen M; Gomes ME; Oude Ophuis T; Troe E; Tonino WA; Konings CJ; de Vries PA; van Balen A; Heeg JE; Smit JJ; Elvan A; Steggerda R; Niamut SM; Peels JO; de Swart JB; Wardeh AJ; Groeneveld JH; van der Linden E; Hemmelder MH; Folkeringa R; Stoel MG; Kant GD; Herrman JP; van Wissen S; Deinum J; Westra SW; Aengevaeren WR; Parlevliet KJ; Schramm A; Jessurun GA; Rensing BJ; Winkens MH; Wierema TK; Santegoets E; Lipsic E; Houwerzijl E; Kater M; Allaart CP; Nap A; Bots ML
Neth J Med; 2016 Jan; 74(1):5-15. PubMed ID: 26819356
[TBL] [Abstract][Full Text] [Related]
32. A cost-effectiveness analysis of celecoxib compared with diclofenac in the treatment of pain in osteoarthritis (OA) within the Swedish health system using an adaptation of the NICE OA model.
Brereton N; Pennington B; Ekelund M; Akehurst R
J Med Econ; 2014 Sep; 17(9):677-84. PubMed ID: 24914585
[TBL] [Abstract][Full Text] [Related]
33. Cost-utility analysis of duloxetine in osteoarthritis: a US private payer perspective.
Wielage RC; Bansal M; Andrews JS; Klein RW; Happich M
Appl Health Econ Health Policy; 2013 Jun; 11(3):219-36. PubMed ID: 23616247
[TBL] [Abstract][Full Text] [Related]
34. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries.
Oostenbrink JB; Rutten-van Mölken MP; Monz BU; FitzGerald JM
Value Health; 2005; 8(1):32-46. PubMed ID: 15841892
[TBL] [Abstract][Full Text] [Related]
35. Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden: a lifetime model based on the CAPRIE trial and high-risk CAPRIE subpopulations.
Logman JF; Heeg BM; Herlitz J; van Hout BA
Appl Health Econ Health Policy; 2010; 8(4):251-65. PubMed ID: 20578780
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of catheter-based radiofrequency renal denervation for the treatment of uncontrolled hypertension: an analysis for the UK based on recent clinical evidence.
Sharp ASP; Cao KN; Esler MD; Kandzari DE; Lobo MD; Schmieder RE; Pietzsch JB
Eur Heart J Qual Care Clin Outcomes; 2024 Jan; ():. PubMed ID: 38196127
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness analysis of single fraction of stereotactic body radiation therapy compared with single fraction of external beam radiation therapy for palliation of vertebral bone metastases.
Kim H; Rajagopalan MS; Beriwal S; Huq MS; Smith KJ
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):556-63. PubMed ID: 25680599
[TBL] [Abstract][Full Text] [Related]
38. Cost effectiveness of prostacyclins in pulmonary arterial hypertension.
Roman A; Barberà JA; Escribano P; Sala ML; Febrer L; Oyagüez I; Sabater E; Casado MA
Appl Health Econ Health Policy; 2012 May; 10(3):175-88. PubMed ID: 22452448
[TBL] [Abstract][Full Text] [Related]
39. Renal Denervation in Asia: Consensus Statement of the Asia Renal Denervation Consortium.
Kario K; Kim BK; Aoki J; Wong AY; Lee YH; Wongpraparut N; Nguyen QN; Ahmad WAW; Lim ST; Ong TK; Wang TD
Hypertension; 2020 Mar; 75(3):590-602. PubMed ID: 32008432
[TBL] [Abstract][Full Text] [Related]
40. Incremental cost-effectiveness of various monthly doses of vardenafil.
Aspinall SL; Smith KJ; Cunningham FE; Good CB
Value Health; 2011 Jan; 14(1):97-101. PubMed ID: 21211491
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
